CommercialPrior AuthMedium impact
Hematopoietic Stem-Cell Transplantation for Breast Cancer
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi has updated their policy on hematopoietic stem cell transplantation for breast cancer, explicitly stating that autologous transplants are not medically necessary and allogeneic transplants are investigational for all stages of breast cancer. Prior authorization through Case Management is required for any covered transplant procedures.
Action Required
Immediately: Billing team must ensure prior authorization through Case Management is obtained before billing any hematopoietic stem cell transplant procedures for breast cancer patients with BCBS Mississippi. Update system alerts to flag these cases as not medically necessary (autologous) or investigational (allogeneic). Claims will be denied without proper authorization.